Nuvalent, Inc. Class A NUVL 深 滬
已收盤 05-08 16:00:00 美东时间
105.28
+2.880
+2.81%
華盛通- 最 高107.52
- 今 開103.19
- 成交量 57.99万股
- 最 低 102.26
- 昨 收 102.40
- 總市值 77.43亿
- 52周最高 113.015
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 70.25
- 委 比 -42.80%
- 總股本 7354.28万
- 歷史最高 113.51
- 量 比 1.09
- 振 幅 5.14%
- 歷史最低 7.09
- 每 手 1
- 風險率 12.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvalent Q1 EPS $(1.39) Misses $(1.36) Estimate
Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.36) by 2.21 percent. This is a 17.8 percent decrease over losses of $(1.18) per share from the same
05-07 18:37
Guardant Health And Nuvalent Enter Strategic Collaboration For The Development And Potential Commercialization Of Nuvalent's Oncology Pipeline Using The Guardant Infinity Platform's Tissue And Liquid Tools
The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations,
04-30 20:12
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
Nuvalent Reports Zidesamtinib Shows Activity In Pre-Treated ROS1+ Lung Cancer With Strong Brain Penetration Data At AACR 2026
Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in those with CNS
04-18 04:02
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
Wedbush Reiterates Outperform on Nuvalent, Maintains $125 Price Target
Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $125 price target.
04-08 20:49
Nuvalent Submits NDA To FDA For Neladalkib, Investigational ALK-Selective Inhibitor, In TKI Pre-Treated Advanced ALK-Positive NSCLC.
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trialCAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage
04-07 18:34
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Wells Fargo Initiates Coverage On Nuvalent with Overweight Rating, Announces Price Target of $116
Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces Price Target of $116.
03-30 21:25
Nuvalent To Present New Clinical And Preclinical Data On Zidesamtinib For ROS1+ NSCLC At AACR 2026
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new data for
03-18 05:22
